Synapsor

Synapsor (欧态科技) is a Chinese AI healthcare company founded in 2019, specializing in intelligent chronic disease management through wearable medical devices and deep learning algorithms. The company develops continuous glucose monitoring (CGM) systems powered by proprietary AI-enabled biosensors, targeting the global population of over 537 million diabetes patients. Synapsor's flagship product is a wearable dynamic blood glucose monitoring device that provides near-painless, real-time glucose tracking and personalized AI-driven analysis through its companion mobile application. The company's AI assistant delivers 24/7 support, performs deep learning from individual user data, and generates customized blood glucose reports and trend analysis. Synapsor aims to make advanced chronic disease monitoring accessible, affordable, and user-friendly, reducing dependence on clinic visits through intelligent self-managed health technology. The company is backed by Shunwei Capital and operates at the intersection of medical devices and artificial intelligence.